logo
Cardano price prediction: ADA's 13% rebound tests $1 breakout zone

Cardano price prediction: ADA's 13% rebound tests $1 breakout zone

Business Mayor23-05-2025

Cardano price prediction turns bullish as ADA jumps 13% after a clean retest of the $0.7125 support level.
Whale wallets began accumulating long positions, anticipating a breakout toward the $1.15 liquidity zone.
Cardano [ADA] has come back to life again.
The altcoin recently recovered from the pennant support level at $0.7125, recording a sharp 13% jump in under 72 hours.
This sharp move reignited bullish momentum, and the current Cardano price prediction now centers around a potential break above $1.
The rebound followed a textbook retest, confirming the validity of the pennant formation. For many traders, this solidified ADA's short-term bullish structure.
With momentum building, the market now watches for a clean push through the $1 mark—a critical psychological and technical level.
Source: TradingView
Liquidity at $1.15 generates notice
ADA recent price spike of could be due to a larger goal — the equal highs liquidity pool at around $1.15 level. This region resulted in several rejections, with untouched liquidity left behind.
Prices usually push towards these key zones, especially on buildups of momentum. With $1 as a potential point of entry, a break can propel gains.
Reaching $1.15 would not only sweep the liquidity levels clean, but also confirm bullish control on the higher time frames.
Interestingly, the position here is consistent with classical breakout patterns.
The pennant formation commonly leads to a continuation in the earlier trend direction — in this case, ADA bullish trends may prevail further.
Whale activity validates bullish outlook
Adding confidence to the bullish Cardano price prediction is fresh whale accumulation.
AMBCrypto analysis of CryptoQuant's on-chain data indicated that whales are beginning to accumulate again.
Read More Ethereum hits $3.7K as whales accumulate, but there's a problem
High-net-worth addresses are opening long positions, suggesting optimism regarding an ADA short-term rally. Whales are the trend setters of big trends.
Their increased activity suggests that smart money is preparing for a breakout above $1.
With liquidity targets converging with the bullish sentiments, ADA may be setting up another bullish run. A clean breakout above $1 with strong follow-through would confirm the bull case.
Source: CryptoQuant
Cardano Price Prediction: Can bulls clear the $1 barrier?
With buyer-friendly technical environments and whale demand on the rise, ADA might be about to test and break the $1 barrier.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Leverage Reconfigures in Q1: DeFi Recovers, CeFi Quietly Expands, Treasury Debt Mounts
Leverage Reconfigures in Q1: DeFi Recovers, CeFi Quietly Expands, Treasury Debt Mounts

Yahoo

timean hour ago

  • Yahoo

Leverage Reconfigures in Q1: DeFi Recovers, CeFi Quietly Expands, Treasury Debt Mounts

Leverage across the crypto economy is evolving, not evaporating. Total crypto-collateralized lending fell 4.9% quarter-over-quarter to $39.07 billion, the first decline since late 2023, Galaxy Research's Q1 2025 report shows. But while the headline figure contracted, underlying dynamics suggest leverage is shifting form, not fading. Lending in decentralized finance (DeFi) lending took a hit early in the quarter, sliding as much as 21%, before rebounding sharply in April and May. The turnaround was driven largely by Aave's integration of Pendle tokens, whose yield-bearing structure and high loan-to-value ratios (up to 90%) sparked a wave of fresh borrowing. By late May, DeFi borrowing had surged more than 30% off the lows, with Ethereum leading the recovery. Centralized finance (CeFi) lending climbed 9.24% to $13.51 billion, led by Tether, Ledn, and Two Prime. Still, Galaxy notes that a narrow set of public disclosures limits visibility into the true scope of centralized lending. Private desks, OTC platforms, and offshore credit providers likely push the actual total far higher. perhaps by 50% or more. Meanwhile, bitcoin BTC treasury companies are quietly becoming a new systemic leverage node. Firms like Strategy (MSTR) have issued billions in convertible debt to fund BTC purchases. As of May, total outstanding debt across treasury firms stood at $12.7 billion, much of it set to mature between 2027 and 2028. In derivatives, CME's rising open interest especially in ether ETH futures signals accelerating institutional participation. At the same time, upstart exchange Hyperliquid has carved out a growing share of the perpetual futures market, underscoring the continued strength of retail-driven leverage. The report points to an increasingly interconnected market structure, one where stress in a single venue or instrument could reverberate quickly across the ecosystem. Leverage, in crypto's current cycle, may be more fragmented than before — but it's no less potent. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Why The Next Internet Isn't Web3—It's Interchain
Why The Next Internet Isn't Web3—It's Interchain

Forbes

time3 hours ago

  • Forbes

Why The Next Internet Isn't Web3—It's Interchain

Wesley is the CEO of FPBlock , helping clients with the latest techniques in functional programming, cloud, DevOps and containerization. getty The early internet wasn't built in neat layers. It was chaotic and fragmented with competing protocols, no clear standards and certainly no centralized gatekeeper. But from that chaos emerged a global network—not by unification but through interoperability. Web3 is following a similar arc. We're witnessing the birth of a new digital terrain—one not owned or ruled by a single entity but composed of many sovereign networks working in parallel. Not one chain to rule them all, but many chains, cooperating across boundaries. Welcome to the Interchain. For years, Web3 debates revolved around dominance. Which chain will win? Will it be Ethereum with its first-mover advantage? Solana with its speed? Bitcoin with its simplicity? But these questions assume a flawed premise—that the blockchain world must mirror the Web2 model: one platform to rule them all, everything else a plug-in. That's not what's happening. Blockchains are emerging as digital nations, not Web2-style platforms. They have unique cultures, governance structures and economies. Ethereum, Solana, Celestia, Bitcoin—each has its own purpose, priorities and strengths. Like nations, their power lies in their sovereignty. Interchain is not about centralizing power—it's about collaborating across it. Sovereign, Composable And Specialized Established networks and emerging modular blockchains are pioneering this vision. They're not trying to consolidate chains. Instead, they're making them interoperable by making them: • Sovereign: Each chain operates under its own rules, governance and upgrade schedule. • Composable: Chains can exchange assets and messages freely via standards like Inter-Blockchain Communication (IBC) or trust-minimized bridges. • Specialized: Chains are optimized for what they do best—whether that's decentralized finance (DeFi), gaming, identity or AI. This is the Interchain philosophy: Build small, build sovereign and connect everything. Understanding The Kolme Framework For The Interchain Era The Kolme Framework is a modular blockchain infrastructure that enables developers to build application-specific chains with native cross-chain communication. Designed for the Interchain era, Kolme simplifies interoperability, abstracts the complexities of multichain development and accelerates time-to-market without compromising sovereignty or security. This framework introduces structured interoperability to a diverse blockchain ecosystem. Rather than enforcing uniformity, it standardizes communication while allowing each chain to maintain its independence. This approach strengthens the Interchain in four key ways: • Seamless Cross-Chain Experiences: Asset and data transfers are not only technically smooth—they're intuitive for users as well. • Scalability Through Modular Architecture: By distributing processing across sovereign chains, Kolme reduces bottlenecks and enhances performance. • Security-First Interoperability: Robust standards reduce vulnerabilities common in early bridge technologies and improvised integrations. • Support For Modular Blockchain Design: Chains can remain specialized and agile, while Kolme ensures they stay connected and collaborative. Kolme isn't just building tools—it's laying the digital highways between decentralized cities. The outcome: a thriving digital economy marked by fluid movement, shared innovation and resilient infrastructure. The Impact Of Interchain While monolithic blockchains concentrate power and risk, Interchain helps disperse both. The benefits are: • Resilience: There is no single point of failure. If one chain halts, the others continue. • Innovation: Sovereign chains evolve independently, pioneering and sharing breakthroughs. • Freedom: Builders and users can move between ecosystems—or create entirely new ones—with fewer barriers. Where Web2 stacked vertical layers, Interchain is horizontal—a flat, open space where ideas travel, chains specialize and users roam. What This Means For You Whether you're a founder, investor or everyday user, the rise of the Interchain is reshaping core assumptions. For founders, it's no longer about building for a single chain—it's about building for a network. Applications should be designed to plug into an evolving, interconnected ecosystem rather than being tied to one specific host. For users, the expectation is shifting toward seamless portability—your identity, assets and permissions should move with you across chains, wallets and decentralized applications. For investors, the strategy must evolve beyond backing isolated winners; the real opportunity lies in funding foundational primitives, interoperability standards and coordination layers. This isn't a move toward one dominant chain, but rather a platform shift toward a cooperative constellation of networks. The Road Ahead: Friction, Then Flight The vision is clear, but the path to get there is still bumpy as Interchain adoption comes with challenges. For starters, security is a major concern—cross-chain interactions add complexity and introduce new risks, and the guardrails to protect against them are still evolving. Scalability also presents a tension between sovereignty and efficiency; not every interaction requires validation on a global ledger, and systems must account for that. User experience is another critical area—signing multichain transactions and juggling multiple wallets is cumbersome, and these processes must become significantly more seamless. Finally, governance must adapt. As chains increasingly cooperate, governance structures will need to evolve from isolated forums into coordinated networks capable of managing collective decision making across ecosystems. However, these are growing pains, not fatal flaws. To overcome Interchain's challenges, the ecosystem must adopt a few key principles: 1. Security must be standardized across bridges and messaging layers through rigorous auditing, formal verification and shared security models. 2. User experience needs to become seamless: wallet providers, user interface (UI) designers and protocol teams should collaborate on abstracting away chain-specific details. 3. Interoperability standards like inter-blockchain communication (IBC) should be adopted broadly to reduce fragmentation. 4. Governance coordination must evolve by enabling on-chain collaboration across networks, not just within them. Together, these steps can turn early friction into future fluidity. The early internet didn't start with clean user experiences or rock-solid standards. It grew into them. I believe Interchain will, too. Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?

Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®
Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®

Yahoo

time4 hours ago

  • Yahoo

Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®

Four presentations on MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, including two clinical data presentations Additional preclinical presentations on other differentiated portfolio assets, including MET-233i, a monthly, ultra-long acting amylin analog NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, will highlight the breadth and momentum of its portfolio of ultra-long acting, scalable, and combinable therapies, including updated clinical and preclinical findings from lead program MET-097i, at the 85th Scientific Sessions of the American Diabetes Association® (ADA). 'We look forward to presenting work spanning our portfolio to the scientific community at this year's ADA meeting,' said Whit Bernard, Chief Executive Officer of Metsera. 'Our presentations, including clinical data from the completed Phase 1/2 trial of MET-097i and preclinical findings for our other programs, showcase the breadth of our next-generation approaches to address the need for scalable and differentiated treatments for overweight and obesity.' Presentation Highlights MET-097i: A fully biased, ultra-long acting GLP-1 receptor agonist MET-097i is Metsera's fully biased, monthly, ultra-long acting GLP-1 receptor agonist. Metsera will present clinical data from MET-097i's Phase 1/2 clinical trial in two presentations, including change in body weight and tolerability data after twelve weekly doses and after a single candidate monthly dose. MET-233i: An ultra-long acting amylin analog MET-233i is Metsera's monthly, ultra-long acting amylin analog. Metsera will present preclinical data, including detailed pharmacokinetic and change in body weight data. Presentation Details: MET-097i: A fully biased ultra-long acting GLP-1 receptor agonist Clinical data Title: A Twelve-Week Trial of MET-097—A Potent and Ultra-Long-Acting GLP-1 Receptor Agonist (788-P)Session: Sunday General Poster SessionPresenter: Robert Stoekenbroek, M.D., Ph.D., Head of Portfolio Strategy at Metsera Time/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 122 Title: Safety, Tolerability, PK, and Efficacy of MET-097—A Next-Generation Nutrient-Stimulated Hormone Peptide Analog for Chronic Weight Management (753-P)Session: Sunday General Poster SessionPresenter: Steve Marso, M.D., Chief Medical Officer at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 088 Preclinical data Title: MET-097: Preclinical Characterization of a Potent and Ultra-Long-Acting GLP-1 Receptor Agonist (794-P)Session: Sunday General Poster SessionPresenter: Charlotte Hinds, Ph.D., Senior Director, Research & Development at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 128 Title: Cellular Characterisation of Signalling and Receptor Trafficking Induced by MET-097, a G Protein-Biased GLP-1R Agonist (799-P)Session: Sunday General Poster SessionPresenter: Billy Peter Baxter, Ph.D., Imperial College LondonTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 133 MET-233: An ultra-long acting amylin analog Preclinical data Title: MET-233 Is an Ultra-Long-Acting Amylin Receptor Agonist (894-P)Session: Sunday General Poster SessionPresenter: James S Minnion, Ph.D., Vice President, Research & Development at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 190 Pipeline programs Preclinical data Title: Therapeutic NuSH Cocktails—Coadministration of Ultra-Long-Acting GLP-1, GIP, Glucagon, and Amylin Peptide Analogs Induce Profound Weight Loss in DIO Mice (765-P)Session: Sunday General Poster SessionPresenter: Robert Hansford, Ph.D., Preclinical Research Scientist at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 100 Health Economics and Outcomes Research Title: Titration to Maintenance Doses of GLP-1R Agonists for Overweight and Obesity Is Suboptimal for Majority of Patients—Evidence from a Real-World Claims Dataset (758-P)Session: Sunday General Poster SessionPresenter: Shannon Armstrong, Vice President, Global Value and Access at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 093 For more information about Metsera's presence at ADA, visit About Metsera Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera was founded in 2022 and is based in New York City. For more information, please visit us at and follow us on LinkedIn and X. Metsera may use its website as a distribution channel of material information about the Company. Financial and other important information regarding the Company is routinely posted on and accessible through the Investors & News section of its website at In addition, you may sign up to automatically receive email alerts and other information about the Company by using the 'Email Alerts' option on the Investors & Media page and submitting your email address. Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Examples of such statements include, but are not limited to, statements relating to Metsera's expectations regarding participation and presentations at the 85th Scientific Sessions of the American Diabetes Association® (ADA), its research and development activities, and statements regarding the efficacy, safety and potential regulatory progress of its investigational candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Metsera's business outlined in Metsera's filings with the Securities and Exchange Commission, including in the 'Risk Factors' section of its Annual Report on Form 10-K for the year ended December 31, 2024. Forward-looking statements are not guarantees of future performance, and Metsera's actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Metsera makes in this press release speak only as of the date of this press release. Metsera assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact:Jono EmmettMetseramedia@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store